Warren, Jayapal Blast Big Pharma's Sham Patent Claims, Urge Companies to End Abusive Patent Practices that Cost Patients Billions

Press Release

"The FTC pledged to scrutinize companies that engage in these practices for violating Section 5 of the Federal Trade Commission Act, and in November issued a warning letter to (your company) that appears to conclude that the company may be violating federal law with regard to its drug listings. Given these concerns, we urge you to voluntarily de-list the patents named in the FTC's letter that you have listed in the Orange Book, and any other patents you have listed that unfairly block competition.

We have long been concerned by these and other pharmaceutical industry abuses of the patent system to stifle competition, prolong drug monopolies, and price-gouge patients. FDA has acknowledged these Orange Book-related issues and taken some steps to "ensure our system, as a whole, is not used to improperly delay getting more affordable drugs and biosimilars into the hands of Americans who need them."

Source